RSA Launches ID Plus Sovereign Deployment: The Next Level of High Assurance Identity Security
23.3.2026 12:00:00 EET | Business Wire | Press release
Today at RSAC Conference 2026, RSA, the security-first identity leader, announced the launch of RSA® ID Plus Sovereign Deployment, a groundbreaking evolution in high assurance identity solutions designed to meet the needs of organizations that must maintain constant availability, meet policy and data sovereignty laws, and defend themselves from advanced, persistent threats.
RSA ID Plus Sovereign Deployment is the next evolution in RSA® ID Plus, the market’s most secure identity and access management (IAM) security platform featuring complete multi-factor authentication (MFA), SSO, and access capabilities. RSA ID Plus Sovereign Deployment features a new “deploy anywhere” capability that allows government agencies, financial services, critical infrastructure, and healthcare organizations to modernize their identity infrastructure while still maintaining the highest standards in security, availability, and regulatory compliance.
Unlike other vendors that offer limited technology or reduced capabilities depending on an organization’s licenses and choices, RSA strongly believes in offering full-stack identity capabilities no matter the environment. RSA ID Plus Sovereign Deployment’s deploy anywhere capability allows organizations to deploy modern, full stack identity capabilities wherever they choose, including private cloud, multi-cloud, on-premises, and air-gapped configurations. This capability allows government agencies, financial services, critical infrastructure, and healthcare organizations to modernize their identity infrastructure while still maintaining the highest standards in security, availability, and regulatory compliance.
“RSA ID Plus Sovereign Deployment is a direct response to the intensifying regulatory landscape, operational realities, and emerging threats that our customers face,” said RSA CEO Greg Nelson. “We built this solution for high-assurance organizations where failure is not an option and where compromise is a non-starter. RSA ID Plus Sovereign Deployment ensures that government agencies, financial services, healthcare, and critical infrastructure maintain the highest standards for data sovereignty, regulatory compliance, and security integrity.”
“In a threat landscape where standing still is its own vulnerability, RSA is raising the bar,” said RSA Federal and Strategic President Kevin Orr. “RSA ID Plus Sovereign Deployment is the first and only full stack identity solution that enables government agencies, financial services, critical infrastructure, and healthcare organizations to modernize their identity infrastructure while meeting regulatory requirements and supporting operational complexity—without ever compromising on security or availability.”
RSA ID Plus Sovereign Deployment surpasses compliance requirements and is engineered to secure the organizations with the most to lose. The solution is aligned with Executive Order 14028, OMB M-22-09, OMB M2-24-14, NIS2, DORA, and global cybersecurity and data sovereignty mandates. Whether deployed in private cloud, multi-cloud, on-premises, and air-gapped configurations, ID Plus Sovereign Deployment puts organizations in control—defending sensitive data against the world’s most persistent and well-funded adversaries, even when connectivity fails. The solution delivers:
- Unified authentication, access, directory, and identity governance and administration (IGA) everywhere: private cloud, multi-cloud, on-premises, and air-gapped configurations—meeting organizations where their risk resides, not where a vendor’s limitations end
- End-to-end phishing resistant passwordless authentication that eliminates the most frequent and highest impact attack vector across cloud, desktop, and datacenter, with multiple options for offline passwordless—so security holds even if everything else breaks
- Secure access against advanced threats and bypass attacks that go beyond phishing with RSA® Mobile Lock and RSA® Risk AI
- Help Desk fraud prevention via RSA® Help Desk Live Verify
- Enhanced resilience: RSA ID Plus Sovereign Deployment can be deployed with RSA Authentication Manager to provide redundant authentication and access capabilities during cloud outages
RSAC Conference attendees are welcome to join RSA at Booth N 6253 to preview RSA ID Plus Sovereign Deployment.
Resources
- Book a demo with RSA at RSAC 2026
- RSA® ID Plus Sovereign Deployment solution brief
- RSA® Mobile Lock
- RSA® Risk AI
- RSA® Help Desk Live Verify
About RSA
The AI-powered RSA Unified Identity Platform protects the world’s most secure organizations from today’s and tomorrow’s highest-risk cyberattacks. RSA provides the identity intelligence, authentication, access, governance, and lifecycle capabilities needed to prevent threats, secure access, and enable compliance. More than 9,000 security-first organizations trust RSA to manage more than 60 million identities across on-premises, hybrid, and multi-cloud environments. For additional information, visit our website to contact sales, find a partner, or learn more about RSA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260323041960/en/
Contacts
teamrsa@axicom.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom